Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.55 |
| ▸ | CTSS | P25774 | 8/20 | 0.53 |
| ▸ | CTSK | P43235 | 7/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6163926 | 0.91 | USP30 (0.57) | USP30CTSSCTSKCTSBCTSL | |
| SCHEMBL6166654 | 0.88 | USP30 (0.54) | USP30CTSSCTSKCTSBCTSL | |
| SCHEMBL6166435 | 0.85 | USP30 (0.59) | USP30 | |
| SCHEMBL6164417 | 0.81 | PTPN1 (0.59) | USP30CTSSCTSKCTSBCTSL | |
| SCHEMBL6164079 | 0.80 | USP30 (0.48) | USP30CTSSCTSKCTSBCTSL | |
| SCHEMBL6161556 | 0.79 | CTSS (0.53) | USP30CTSSCTSKCTSBCTSL | |
| SCHEMBL6163324 | 0.78 | USP30 (0.56) | USP30 | |
| SCHEMBL2999836 | 0.73 | CTSS (0.69) | CTSSCTSKCTSBCTSL | |
| SCHEMBL2999840 | 0.73 | CTSS (0.69) | CTSSCTSKCTSBCTSL | |
| SCHEMBL30895303 | 0.73 | CTSS (0.61) | USP30CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | USP30 4394/4885CTSS 354/4885CTSK 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.